REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed
or progressed after two prior therapies, one of which included bortezomib
REVLIMID is not indicated and not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL)
outside of controlled clinical trials
VISIT ASH BOOTH #805 TO LEARN MORE ABOUT REVLIMID
TOGETHER WE STRIVE
TO SHAPE
EXPECTATIONS
for patients with relapsed or
refractory mantle cell lymphoma
Print-only content
WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY,
and VENOUS and ARTERIAL THROMBOEMBOLISM
See full prescribing information for complete boxed warning.
EMBRYO-FETAL TOXICITY
• Lenalidomide, a thalidomide analogue, caused limb abnormalities in
a developmental monkey study similar to birth defects caused by
thalidomide in humans. If lenalidomide is used during pregnancy,
it may cause birth defects or embryo-fetal death.
•
Pregnancy must be excluded before start of treatment. Prevent
pregnancy during treatment by the use of two reliable methods
of contraception.
REVLIMID is available only through a restricted distribution program
called the REVLIMID REMS® program (formerly known as the
“RevAssist® program”).
HEMATOLOGIC TOXICITY. REVLIMID can cause significant neutropenia
and thrombocytopenia.
•
For patients with del 5q myelodysplastic syndromes, monitor
complete blood counts weekly for the first 8 weeks and
monthly thereafter.
For more information, please visit www.REVLIMID.com or call 1-888-423-5436.
VENOUS AND ARTERIAL THROMBOEMBOLISM
REVLIMID is only available through a restricted distribution program,
REVLIMID REMS®.
•
Please see Important Safety Information, including Boxed WARNINGS,
and Brief Summary of full Prescribing Information on the
following pages.
Significantly increased risk of deep vein thrombosis (DVT)
and pulmonary embolism (PE), as well as a risk of myocardial
infarction, and stroke in patients with multiple myeloma
receiving REVLIMID with dexamethasone. Anti-thrombotic
prophylaxis is recommended.